BOARD OF DIRECTORS

Dr. Bednarski is a partner at MVM Life Sciences, a venture capital firm that invests in technologies and products for the life science and healthcare markets, with over $500 million under management.  He joined MVM in 2008 from Advent International in Boston where he was involved in several healthcare investments.  Prior to Advent, Dr. Bednarski served as a director in the corporate finance group of Silicon Valley Bank.  He previously worked in the drug discovery group of Dupont-Merck Pharmaceuticals.  Dr. Bednarski holds a Ph.D. in neurobiology from the University of California and a B.S. from Brown University.

Mr. Brand has more than three decades of pharmaceutical industry experience.  Prior to Tarsa, he served as CEO and president of Cardiokine, where he led strategic and organizational development and negotiated a significant global agreement with Biogen Idec for late stage development and marketing of lixivaptan.  Previously, Mr. Brand spent over 30 years at GlaxoSmithKline and its predecessor companies.  Most recently, he headed the U.S. GI/CNS, product development, metabolic and cardiovascular business units, leading the U.S. launches of Paxil®, Requip® and Avandia®, the pre-launch development of Coreg®, Kytril® and Augmentin® ES/XR, and many co-marketing and licensing deals.  Earlier, Mr. Brand held international senior management positions in marketing, acquisitions, business development and regional country management.  He currently serves on the board of directors at Intekrin Therapeutics.  Mr. Brand holds a bachelor of commerce degree from Concordia University in Montreal.

Dr. Edwards is a senior partner at Novo A/S, a global life science venture capital firm that invests more than $100 million annually.  Prior to Novo, Dr. Edwards served as CEO of ReNeuron Holdings, taking the company public in 2000.  Earlier, he was corporate vice president and head of drug development for Novo Nordisk A/S.  Previously, he served as senior vice president for medical affairs at Novo Nordisk and as vice president of pharmacology and medical affairs of ZymoGenetics.  Dr. Edwards currently serves as a director of several life sciences firms and is chairman of Symphogen A/S.  He holds degrees in physiology and medicine from Manchester University, as well as post graduate medical diplomas from the London Royal Colleges and an M.B.A. from Warwick University.  Dr. Edwards is also adjunct professor of management at the Scandinavian Management Institute (SIMI) in Copenhagen and Copenhagen Business School (CBS).

Mr. Palmer currently serves as president and CEO of Unigene.  Prior to Unigene, he served as CEO of Critical Biologics Corporation, a critical care company where he remains a director, and also headed the strategic advisory firm, Creative BioVentures™ Corporation.  Previously, Mr. Palmer served as president and CEO of INO Therapeutics, Inc., a spin-out of the nitric oxide assets of Ohmeda, Inc., which commercialized the world's first selective pulmonary vasodilator.  Earlier, he served as vice president of business development at Ohmeda, where he played a key role in the sale of Ohmeda to a consortium including Baxter and Becton, Dickinson.  Mr. Palmer holds an M.B.A. from the University of Bradford, England and a B.Sc. from the University of Manchester, England.

Dr. Rieke is a founding principal and is currently a partner at Quaker Partners, a venture capital firm investing in the life science industry with over $700 million under management. In addition to Tarsa, Dr. Rieke is on the board of directors of a number of human therapeutic and medical device companies.  Dr. Rieke was a founding principal of Quaker Partners, which he joined from PA Early Stage, a venture capital fund investing in early-stage life science and IT companies.  Prior to entering venture capital, he established several start-up companies based on technologies from the University of Pennsylvania Center for Technology Transfer and served as a management consultant with CSC Healthcare, focusing on disease management protocols.  Dr. Rieke holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. from Colgate University.  He maintains an active medical license.

Dr. Tananbaum is the founding CEO of Foresite Capital Management. He has led investments in 21 successful healthcare companies, including Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Amerigroup and Jazz Pharmaceuticals. Previously, Dr. Tananbaum founded and held management positions at GelTex Pharmaceuticals (acquired by Genzyme for $1.6B) and Theravance. He holds an M.D. from Harvard Medical School and an M.B.A from Harvard Business School, and a B.S. and B.S.E.E. from Yale University. Dr. Tananbaum has served on the advisory boards and/or visiting committees to the Harvard-MIT HST program and Yale School of Engineering.